ledipasvir and Anemia--Sickle-Cell

ledipasvir has been researched along with Anemia--Sickle-Cell* in 1 studies

Other Studies

1 other study(ies) available for ledipasvir and Anemia--Sickle-Cell

Article	Year
Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Sep-01, Volume: 65, Issue:5 Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population. Topics: Adult; Anemia, Sickle Cell; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Young Adult	2017

Article

Year

Efficacy and Safety of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in Persons With Sickle Cell Disease.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017, Sep-01, Volume: 65, Issue:5

Patients with sickle cell disease are at high risk for chronic hepatitis C infection. Prior treatment has been limited due to the use of ribavirin causing hemolytic anemia and interferon causing cytopenias. We demonstrate the safety and efficacy of fixed-dose combination ledipasvir and sofosbuvir for 12 weeks in this population.

Topics: Adult; Anemia, Sickle Cell; Antiviral Agents; Benzimidazoles; Drug Combinations; Female; Fluorenes; Hepatitis C, Chronic; Humans; Male; Middle Aged; Sofosbuvir; Young Adult

2017